PUT CHEMO TO THE TEST

Do you really need chemotherapy for your early-stage breast cancer? The Oncotype DX test is the only way to know if you will benefit from chemotherapy or not.

Start Over

We Put Chemo to the Test with Oncotype DX
Diane, Katherine, Deepa, Laurie, Coree, Susan, Lynda
Are you eligible?

Find Out If the Oncotype DX Test Is Right For You

Take our simple quiz to determine if the Oncotype DX test can help guide your treatment decision.

  • Oncotype DX Quiz

    Are you a newly diagnosed breast cancer patient or caregiver trying to determine what treatment plan is right for you or a loved one?

    Back Next
    Choose an answer to proceed

    The Oncotype DX breast cancer test is a genomic test that may help guide treatment decisions for patients with non-invasive breast cancer, often referred to as ductal carcinoma in situ (DCIS), and help early-stage invasive breast cancer patients with estrogen receptor-positive (ER+) HER2 negative disease with node negative or up to three positive lymph nodes evaluate if they will benefit from chemotherapy.

    If you are a caregiver looking for support or additional information about breast cancer, please consider visiting: www.cancercare.com

    Return to the eligibility start page.

    If you would like to speak about the Oncotype DX test with a knowledgeable customer service specialist at Exact Sciences, please call: 855.5000.ASK (855-500-0275).

  • Oncotype DX Quiz

    What stage is your breast cancer?

    I'm not sure. How do I find out what stage my breast cancer is?
    Back Next
    Choose an answer to proceed
    X

    Breast Cancer Stages

    Cancer staging is the assessment of how far a person's breast cancer has progressed and influences treatment decisions and prognosis. Breast cancer staging is a classification method based on the size of your cancer and how far it has (or hasn’t) spread beyond its original location within the breast. It is usually determined after your tumor is removed and your lymph nodes have been examined, although additional blood and imaging tests may also be needed. Your medical team can provide you with a copy of your pathology report.

    Read more or call us 855.5000.ASK (855-500-0275).

    Based on your responses, it appears that you have pre-invasive (Stage 0) breast cancer – known medically as ductal carcinoma in situ – with no lymph node involvement.

    Because DCIS is non-invasive, chemotherapy is never recommended. You may be a candidate for the Oncotype DX DCIS test. Learn more about your treatment options for DCIS breast cancer at MyBreastCancerTreatment.org.

    Learn More About DCIS

    Based on your response, it appears that you have breast cancer that is classified as Stage IIIb or above.

    The Oncotype DX breast cancer test is a genomic test that may help guide treatment decisions for patients with non-invasive breast cancer, often referred to as ductal carcinoma in situ (DCIS), and help early-stage invasive breast cancer patients with estrogen receptor-positive (ER+) disease with up to three positive lymph nodes evaluate if they will benefit from chemotherapy.

    For information on Stage IIIb or above disease, please consider the following resources:

     

    If you have questions and would like to speak about the Oncotype DX test with a knowledgeable customer service specialist at Genomic Health, please call: 855.5000.ASK (855-500-0275).

  • Oncotype DX Quiz

    Has your breast cancer been diagnosed as estrogen receptor positive (ER+)?

    I'm not sure. How do I find out if my cancer is estrogen receptor-positive?
    Back Next
    Choose an answer to proceed
    X

    Estrogen Receptor Status

    Hormones are naturally occurring chemicals in the body that stimulate the growth of hormone-sensitive tissues, such as those in the breast. In some cases of breast cancer, the hormones estrogen and progesterone may stimulate tumor growth. Your doctor will likely have your tumor tested to find out if your cancer is hormone-dependent.

    Your hormone receptor status in the cancer is important in determining the appropriate treatment options for your breast cancer. If you do not know your hormone receptor status, please check with your physician.

    Read more or call us 855.5000.ASK (855-500-0275).

    Based on your response, it appears that your Stage I/II/IIIa breast cancer is not estrogen receptor-positive (ER+).

    The Oncotype DX breast cancer test is a genomic test that may help guide treatment decisions for patients with non-invasive breast cancer, often referred to as ductal carcinoma in situ (DCIS), and help early-stage invasive breast cancer patients with estrogen receptor-positive (ER+) disease with up to three positive lymph nodes evaluate if they will benefit from chemotherapy.

    For information on treatment options for estrogen receptor-negative breast cancer, please consider visiting: www.breastcancer.org.

    If you have questions and would like to speak about the Oncotype DX test with a knowledgeable customer service specialist at Genomic Health, please call: 855.5000.ASK (855-500-0275).

  • Oncotype DX Quiz

    Has your breast cancer been diagnosed as human epidermal growth factor receptor-positive (HER2+)?

    I’m not sure. How do I find out if my cancer is Human Epidermal Growth Factor Receptor 2 (HER2)-positive?
    Back Next
    Choose an answer to proceed
    X

    Human Epidermal Growth Factor Receptor 2 (HER2) Status

    A protein that appears in the cancer cells of some women with breast cancer. A woman whose tumor has greater than normal levels of HER2 is considered HER2 positive. A woman whose tumor has normal levels of HER2 is considered HER2 negative. Cancer cells that have high levels of HER2 tend to grow quickly and respond well to anti-HER2 therapy.

    Your Human Epidermal Growth Factor Receptor 2 (HER2) status is important in determining the appropriate treatment options for your breast cancer. If you do not know your hormone receptor status, please check with your physician.

    Read more or call us 855.5000.ASK (855-500-0275).

    Based on your response, it appears that your Stage I/II/IIIa breast cancer is not estrogen receptor-positive (ER+) or is HER2 positive.

    The Oncotype DX breast cancer test is a genomic test that may help guide treatment decisions for patients with non-invasive breast cancer, often referred to as ductal carcinoma in situ (DCIS), and help early-stage invasive breast cancer patients with estrogen receptor-positive (ER+) HER2 negative disease with node negative or up to three positive lymph nodes evaluate if they will benefit from chemotherapy.

    For information on treatment options for estrogen receptor-negative breast cancer, please consider visiting: www.breastcancer.org.

    Return to the eligibility start page.

    If you have questions and would like to speak about an Oncotype DX test with a knowledgeable customer service specialist at Genomic Health, please call: 855.5000.ASK (855-500-0275).

  • Oncotype DX Quiz

    Does your breast cancer have lymph node involvement?

    I’m not sure. How do I find out I have lymph node involvement?
    Back Next
    Choose an answer to proceed
    X

    Lymph Node Involvement

    If a woman diagnosed with breast cancer has lymph node involvement, it means that her cancer has spread from her original breast tumor to the underarm lymph nodes on the side of her breast cancer. Lymph node status is determined when your doctor removes one or several of your lymph nodes so they can be examined under a microscope for cancer cells.

    Read more or call us 855.5000.ASK (855-500-0275).

    Based on your responses, it appears that you have early-stage invasive breast cancer that is estrogen receptor-positive (ER+) and that you may be a candidate for the Oncotype DX breast cancer test.

    Download the following PDF resources to help you discuss the Oncotype DX test with your physician:

    Doctor Discussion Guide for Invasive Breast Cancer

    Invasive Breast Cancer (Stage I-IIIa) Patient Guide

    If you have questions and would like to speak about the Oncotype DX test with a knowledgeable customer service specialist at Genomic Health, please call: 855.5000.ASK (855-500-0275).

    Based on your responses, it appears that you have Stage I/II/Stage IIIa breast cancer that is estrogen receptor-positive (ER+) and that has spread to one to three lymph nodes. You may be a candidate for the Oncotype DX Breast Recurrence Score test.

    Download the following PDF resources to help you discuss the Oncotype DX test with your physician:

    Doctor Discussion Guide for Invasive Breast Cancer

    Invasive Breast Cancer (Stage I-IIIa) Patient Guide

    If you have questions and would like to speak about the Oncotype DX test with a knowledgeable customer service specialist at Genomic Health, please call: 855.5000.ASK (855-500-0275).

    Based on your response, it appears that your Stage I/II/IIIa breast cancer that has spread to more than three lymph nodes.

    The Oncotype DX Breast Recurrence Score test is a test that may help guide treatment decisions for early-stage invasive breast cancer patients with estrogen receptor-positive (ER+) disease with up to three positive lymph nodes evaluate if they will benefit from chemotherapy.

    For information on treatment options for lymph-node positive breast cancer that has spread to more than three lymph nodes:

     

    If you have questions and would like to speak about the Oncotype DX test with a knowledgeable customer service specialist at Genomic Health, please call: 855.5000.ASK (855-500-0275).

COUNT ME IN

JOIN THE COMMUNITY OF MORE THAN ONE MILLION WOMEN WHO HAVE PUT CHEMO TO THE TEST
Share

About the Oncotype DX Test

The Oncotype DX test definitively identifies the vast majority of women with early-stage breast cancer who will not benefit from chemotherapy as well as the important minority of women for whom chemotherapy can be life-saving. The test provides a personalized score based on the biology of your tumor that can help tailor treatment decisions for your individual cancer. Watch the video to learn more.

Questions To Ask Your Doctor About the Oncotype DX Test

The decision to take the Oncotype DX test for early-stage breast cancer is one that you and your doctor should make together. Download our Doctor Discussion Guide for a list of questions to help you prepare for your appointment.

Transforming The Treatment of Breast Cancer

The landmark TAILORx global study delivered unprecedented results for women with early-stage breast cancer*. Over a 9-year period it confirmed that the Oncotype DX Breast Recurrence Score test definitively predicts who will benefit from chemotherapy. The results may surprise you. Watch the video to learn more about the study.

* For early-stage, ER+, HER2-, NODE- breast cancer